Which stock wins in a matchup between a top U.S. cannabis operator and a fast-growing Canadian cannabis producer?
A big deal with a medical cannabis company provided a spark for Intrexon.
The price of Rockwell Medical's latest stock offering wasn't right for investors.
Pfizer could be only the first of several to spend billions buying smaller biotech.
Here's why Disney is one of those magical stocks you can hold on to for tremendous long-term profits.
This healthcare giant is hot. But will Abbott's sizzle fizzle or get even hotter?
The big drugmaker is spending more than $11 billion for the cancer-drug specialist.
Pfizer's acquisition of Array appeared to cause investors to wonder whether a big deal could be in store for Iovance.
First, there's that terrific dividend. But AbbVie offers even more.
Most cannabis companies are losing money. These aren't.
Not all stocks are expensive. These drug stocks look like bargains.
Which stock wins in a battle between the biggest cannabis producer by market cap and the biggest supplier to the cannabis industry?
Two biotechs that don't have approved drugs yet. One clear winner.
Between this unlikely pair, which stock is the better pick for long-term investors?
The clock is ticking for Celgene's acquisition by Bristol-Myers Squibb. But is Celgene still a stock worth buying?
Which stock wins in a matchup between an up-and-coming Canadian cannabis producer and a U.S. hemp CBD leader?
Growth in the demand for telehealth services, combined with a great strategy, should help this stock win over the next decade.
Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.
Disappointed with its latest quarterly results? The cannabis producer's CEO identified plenty of good news that should be on the way.
Weak quarterly results weighed on the cannabis extraction company's shares.